InMed Pharmaceuticals Inc.
INM
$2.96
$0.24378.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -24.60% | 2.26% | 3.42% | 60.75% | 62.54% |
| Total Depreciation and Amortization | -4.23% | 0.54% | 1.43% | 0.75% | -0.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 46.01% | 537.72% | -28.35% | -97.34% | -97.51% |
| Change in Net Operating Assets | 76.29% | 10.38% | 34.74% | 22.65% | 81.74% |
| Cash from Operations | -15.08% | 7.82% | 4.08% | 38.02% | 55.89% |
| Capital Expenditure | 100.00% | 94.25% | 94.25% | 66.54% | -4,652.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Investing | 100.00% | 98.59% | 98.59% | 96.83% | 86.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.65% | 31.67% | -51.45% | -67.17% | -67.17% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 55.64% | -231.98% | -- | -14.62% | -14.62% |
| Cash from Financing | -74.36% | 4.59% | -56.42% | -70.42% | -70.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -218.91% | 55.77% | -185.57% | -154.06% | -1,210.36% |